Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0941 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0941 Free Base SCHEMBL826456 | 1.00 | GCK (1.00) | GCKKCNH2 | |
| Mk-0941 Free Base SCHEMBL29694365 | 1.00 | GCK (1.00) | GCKKCNH2 | |
| Mk-0941 Free Base SCHEMBL2889404 | 0.98 | GCK (0.97) | GCKKCNH2 | |
| SCHEMBL13255221 | 0.94 | GCK (0.89) | GCKKCNH2 | |
| SCHEMBL3599019 | 0.94 | GCK (0.89) | GCKKCNH2 | |
| SCHEMBL926397 | 0.94 | GCK (0.89) | GCKKCNH2 | |
| SCHEMBL13255210 | 0.93 | GCK (0.88) | GCKKCNH2 | |
| SCHEMBL3594456 | 0.93 | GCK (0.88) | GCKKCNH2 | |
| SCHEMBL3590328 | 0.93 | GCK (0.86) | GCKKCNH2 | |
| SCHEMBL13255208 | 0.93 | GCK (0.86) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2023-07-04 | — | — | US | disclosed |
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2023-07-04 | — | — | US | disclosed |
| US-20220202779-A1 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20200268750-A1 | AGENT | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2020-08-27 | — | — | US | disclosed |
| US-20190328713-A1 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-3556354-A1 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR | Hua Medicine (Shanghai) Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| EP-1600442-B1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | MSD KK (JP) | 2018-01-17 | — | — | EP | disclosed |
| WO-2010107610-A1 | METHOD FOR TREATMENT OF DIABETES AND RELATED CONDITIONS WITH COMBINATION THERAPY AND COMPOSITIONS CONTAINING SUCH COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100222394-A1 | METHOD FOR PRODUCING PYRAZOL-3-YL-BENZAMIDE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100222394-A1 | METHOD FOR PRODUCING PYRAZOL-3-YL-BENZAMIDE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222394-A1 | METHOD FOR PRODUCING PYRAZOL-3-YL-BENZAMIDE DERIVATIVE | CBR3, AADAC, KARS1 | GCK 708/4885KCNH2 449/4885 |
| US-20220202779-A1 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR | GCKR, GCK, HK1 | GCK 2/4885KCNH2 1786/4885 |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | GCK 1/4885KCNH2 470/4885 |
| US-20190328713-A1 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR | GCKR, GCK, HK1 | GCK 2/4885KCNH2 1786/4885 |
| US-20200268750-A1 | AGENT | NFATC1, CX3CR1, CD47 | GCK 35/4885KCNH2 3747/4885 |
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | HK2, PDK1, HK1 | GCK 13/4885KCNH2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.